Published in J Clin Invest on October 01, 1990
Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest (1992) 1.69
Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect Immun (1993) 1.40
Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing. J Exp Med (2014) 0.87
Expression profiling of genes regulated by Fra-1/AP-1 transcription factor during bleomycin-induced pulmonary fibrosis. BMC Genomics (2013) 0.75
Studies of enterobacterial lipopolysaccharides; effects of heat and chemicals on erythrocyte-modifying, antigenic, toxic and pyrogenic properties. J Immunol (1956) 7.13
Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q. J Clin Invest (1974) 5.81
Detection of antibodies and soluble antigen-antibody complexes by precipitation with polyethylene glycol. J Immunol (1973) 4.28
Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J Infect Dis (1985) 3.61
Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes. J Immunol (1967) 3.37
Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem (1980) 3.28
Human alveolar macrophages: comparison of phagocytic ability, glucose utilization, and ultrastructure in smokers and nonsmokers. J Clin Invest (1970) 2.78
Research in cystic fibrosis (third of three parts). N Engl J Med (1976) 2.29
Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest (1984) 1.86
The binding of human immunoglobulin G1 monomer and small, covalently cross-linked polymers of immunoglobulin G1 to human peripheral blood monocytes and polymorphonuclear leukocytes. J Clin Invest (1982) 1.78
Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay. J Clin Invest (1981) 1.57
Role of lipopolysaccharide in opsonization and phagocytosis of Pseudomonas aeruginosa. Infect Immun (1985) 1.54
Immune complexes in cystic fibrosis. Br Med J (1975) 1.36
Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages. Pediatr Res (1979) 1.36
Human gamma-g subclasses. Prog Clin Immunol (1972) 1.35
Detection of immune complexes in human diseases. Prog Allergy (1978) 1.35
The cytotoxic action of leucocidan from Pseudomonas aeruginosa on human polymorphonuclear leucocytes. J Gen Microbiol (1976) 1.34
Circulating immune complexes in Lyme arthritis. Detection by the 125I-C1q binding, C1q solid phase, and Raji cell assays. J Clin Invest (1979) 1.26
Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa. Surv Synth Pathol Res (1985) 1.25
Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis. Am Rev Respir Dis (1980) 1.22
Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Infect Immun (1988) 1.17
Selective inhibition of phagocytic activity of rabbit alveolar macrophages by cystic fibrosis serum. Am Rev Respir Dis (1973) 1.16
Human neutrophils and eosinophils have structurally distinct Fc gamma receptors. J Immunol (1984) 1.15
Neutrophil granulocyte function in patients with pulmonary infection. J Pediatr (1974) 1.13
Characterization of the IgG-Fc receptor on human platelets. Blood (1982) 1.09
Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis. Am Rev Respir Dis (1986) 1.06
125I-Clq-binding and specific antibodies as indicators of pulmonary disease activity in cystic fibrosis. J Pediatr (1981) 1.05
Circulating immune complexes in cystic fibrosis. Pediatr Res (1980) 1.04
Inflammatory reaction and airway damage in cystic fibrosis. J Lab Clin Med (1976) 1.02
Receptors for human IgG subclasses on human alveolar macrophages. Am Rev Respir Dis (1984) 1.01
Immune complexes in the sputum of patients with cystic fibrosis suffering from chronic Pseudomonas aeruginosa lung infection. Acta Pathol Microbiol Scand C (1978) 1.00
Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide. Am Rev Respir Dis (1986) 0.97
Respiratory-mucin inhibition of the opsonophagocytic killing of Pseudomonas aeruginosa. Infect Immun (1988) 0.95
Immune complexes and complement abnormalities in patients with cystic fibrosis. Increased mortality associated with circulating immune complexes and decreased function of the alternative complement pathway. Am Rev Respir Dis (1985) 0.93
Immune complexes in cystic fibrosis. Acta Pathol Microbiol Scand C (1977) 0.93
Combined evaluation of circulating immune complexes and antibodies to Pseudomonas aeruginosa as an immunologic profile in relation to pulmonary function in cystic fibrosis. J Clin Immunol (1987) 0.91
The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen-specific immunotherapy. Allergy (1985) 0.91
Association with phagocytic inhibition of anti-Pseudomonas aeruginosa immunoglobulin G antibody subclass levels in serum from patients with cystic fibrosis. J Clin Microbiol (1986) 0.88
Granulocyte chemiluminescence in adolescent patients with cystic fibrosis. Am Rev Respir Dis (1982) 0.85
Hypergammaglobulinemia in cystic fibrosis. Role of Pseudomonas endobronchial infection. Chest (1987) 0.82
Circulating immune complexes in patients with cystic fibrosis in relation to clinical features. Clin Allergy (1985) 0.78
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med (1999) 3.34
The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med (1997) 2.28
Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest (1984) 1.86
Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest (1998) 1.75
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med (1997) 1.71
Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay. J Clin Invest (1981) 1.57
The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med (1994) 1.44
Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis. Infect Immun (1993) 1.40
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol (1997) 1.29
IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis (1985) 1.25
Cystic fibrosis. J Clin Invest (1987) 1.24
Campylobacter fetus septic arthritis: report of a case. Yale J Biol Med (1979) 1.24
Bronchoalveolar lavage. Thorax (1980) 1.18
Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res (1986) 1.17
Use of Pseudomonas aeruginosa lipopolysaccharide immunoadsorbents to prepare high potency, mono-specific antibodies. J Immunol Methods (1980) 1.12
Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide. Am Rev Respir Dis (1986) 0.97
Alterations in the antibacterial properties of rabbit pulmonary macrophages exposed to wood smoke. Am Rev Respir Dis (1984) 0.92
Biologic activity of purified cotton bract extracts in man and guinea pig. Environ Health Perspect (1986) 0.91
Functional importance of cystic fibrosis immunoglobulin G fragments generated by Pseudomonas aeruginosa elastase. J Lab Clin Med (1989) 0.90
Independent mutations in the flanking sequence of the alpha-1-antitrypsin gene are associated with chronic obstructive airways disease. Dis Markers (1991) 0.89
Airway adherence of Pseudomonas aeruginosa: mucoexopolysaccharide binding to human and bovine airway proteins. J Lab Clin Med (1991) 0.87
IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol (1999) 0.86
Demonstration of a free elastolytic metalloenzyme in human lung lavage fluid and its relationship to alpha 1-antiprotease. Am Rev Respir Dis (1984) 0.85
Pseudomonas aeruginosa and the airways disease of cystic fibrosis. Clin Chest Med (1988) 0.84
Antibody to multiple mucoid strains of Pseudomonas aeruginosa in patients with cystic fibrosis, measured by an enzyme-linked immunosorbent assay. Pediatr Res (1986) 0.83
Modelling asthma in macaques: longitudinal changes in cellular and molecular markers. Eur Respir J (2010) 0.83
Pseudomonas in cystic fibrosis sylph or sycophant? Clin Chest Med (1981) 0.82
Treatment of allergic airways disease with anti-IgE. Allergy (1998) 0.82
Changing spectrum of pneumonia--news media creation or clinical reality? Am J Med (1983) 0.82
Ingestion of hydroxyethyl starch by human leukocytes. Transfusion (1986) 0.81
Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung diseases. Chest (1998) 0.81
Pseudomonas respiratory infection in cystic fibrosis: a possible defect in opsonic IgG antibody? Bull Eur Physiopathol Respir (1983) 0.81
Candidacidal factors in murine bronchoalveolar lavage fluid. Infect Immun (1987) 0.81
Nonbacterial thrombotic endocarditis associated with bone marrow transplantation. Chest (1986) 0.78
Nontuberculous mycobacterial lung disease. Substantiation of a less aggressive approach. Chest (1988) 0.77
Pathogenetic mechanisms in cystic fibrosis lung disease: a paradigm for inflammatory airways disease. J Lab Clin Med (1993) 0.77
Cell-mediated antibacterial defenses of the distal airways. Am Rev Respir Dis (1985) 0.76
Bronchoalveolar lavage in allergic asthmatics. Am Rev Respir Dis (1987) 0.75
Penetration of cefotaxime into respiratory secretions. Antimicrob Agents Chemother (1987) 0.75
Chylothorax as a complication of oesophageal sclerotherapy. Thorax (1992) 0.75
Animals in medical research. Official statement of the American Thoracic Society. Am Rev Respir Dis (1991) 0.75
Introduction: cystic fibrosis lung disease: evolving concepts. Semin Respir Infect (1992) 0.75
Immunoglobulin-E and anti-IgE treatment in lung disease. Monaldi Arch Chest Dis (2001) 0.75
Are lymphocyte beta-adrenoceptors altered in patients with cystic fibrosis? Clin Sci (Lond) (1987) 0.75
Hypogammaglobulinemia in cystic fibrosis. N Engl J Med (1980) 0.75
Immunomodulatory therapies for cystic fibrosis. Semin Respir Infect (1992) 0.75